Roth Affirms Curis (CRIS) at 'Buy' Following Q3 Report, Update; Pipeline Progress is Encouraging
Roth Capital reaffirms its Buy rating and $10 price target on Curis (Nasdaq: CRIS) following Q3 results reported earlier Monday.Analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)